Saizen®

DRUG4 trials

Sponsors

Merck KGaA, Darmstadt, Germany, EMD Serono

Conditions

FibromyalgiaGrowth Hormone Deficiency (GHD)Idiopathic Short StatureSmall Gestational Age (SGA)

Phase 3

Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age

CompletedNCT00249821

Merck KGaA, Darmstadt, GermanySmall Gestational Age (SGA)

Start: 2005-02-28End: 2007-09-30Updated: 2017-09-26

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

CompletedNCT00933686

Merck KGaA, Darmstadt, GermanyFibromyalgia

Start: 2007-12-31End: 2010-07-31Updated: 2013-08-02

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

TerminatedNCT01237340

EMD SeronoGrowth Hormone Deficiency (GHD)

Start: 2010-10-31End: 2011-12-31Updated: 2013-08-07

A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)

CompletedNCT01746862

Merck KGaA, Darmstadt, GermanyIdiopathic Short Stature

Start: 2012-12-31End: 2015-03-31Updated: 2016-10-18

Related Papers

Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature: A Phase III Randomised Controlled Trial.

2018-08-1510 citations

Optimization of growth hormone dosing in children born small for gestational age: an open-label, randomized study of children during the fourth year of therapy.

2012-04-126 citations

Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia.

2012-03-3132 citations